MacroGenics, Inc.

• MacroGenics reports phase 1 data for MGC026 in solid tumors By Investing.com
  Investing.com India · 23 Oct 2026
• MacroGenics, Inc. Estimates – DUS:M55
  TradingView · 23 Oct 2026
• Form 144 MACROGENICS INC. For: 22 October By Investing.com
  Investing.com South Africa · 23 Oct 2026
• Rockville’s MacroGenics Doses First Patient in Phase 1 Study of MGC030, Its Third Clinical-Stage ADC
  BioBuzz · 22 Oct 2026
• Form 144 MACROGENICS INC. For: 22 October By Investing.com
  Investing.com India · 22 Oct 2026
• MacroGenics starts MGC030 trial. MacroGenics stock sits 30.71 percent below high
  AD HOC NEWS · 20 Oct 2026
• First patient dosed in MacroGenics’ Phase I MGC030 trial
  Clinical Trials Arena · 16 Oct 2026
• MacroGenics doses first patient in Phase 1 tria...
  Pluang · 15 Oct 2026
• MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
  The Manila Times · 15 Oct 2026
• MacroGenics (MGNX) Gained +5.35% — Can It Break $3.93? 2026-10-10 - NAAIM Exposure
  https://www.siam.in/ · 10 Oct 2026
• MacroGenics (MGNX) Gained +5.35% — Can It Break $3.93? 2026-10-10 - Sign of Weakness
  https://www.dars.gov.et/ · 10 Oct 2026
• Ezio Bonvini Executes 8,000 MacroGenics Stock Options at $2.60 Each
  Kalkine Media · 07 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →